JP2024540282A5 - - Google Patents
Info
- Publication number
- JP2024540282A5 JP2024540282A5 JP2024526529A JP2024526529A JP2024540282A5 JP 2024540282 A5 JP2024540282 A5 JP 2024540282A5 JP 2024526529 A JP2024526529 A JP 2024526529A JP 2024526529 A JP2024526529 A JP 2024526529A JP 2024540282 A5 JP2024540282 A5 JP 2024540282A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163276117P | 2021-11-05 | 2021-11-05 | |
| US63/276,117 | 2021-11-05 | ||
| EPPCT/EP2022/056991 | 2022-03-17 | ||
| PCT/EP2022/056991 WO2022195011A1 (en) | 2021-03-18 | 2022-03-17 | Psilocybin analogs, salts, compositions, and methods of use |
| PCT/EP2022/076073 WO2023078604A1 (en) | 2021-11-05 | 2022-09-20 | Formulations of psilocybin analogs and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024540282A JP2024540282A (ja) | 2024-10-31 |
| JP2024540282A5 true JP2024540282A5 (https=) | 2025-09-25 |
| JPWO2023078604A5 JPWO2023078604A5 (https=) | 2025-09-25 |
Family
ID=83558221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024526529A Pending JP2024540282A (ja) | 2021-11-05 | 2022-09-20 | シロシビン類似体の製剤および使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250213527A1 (https=) |
| EP (1) | EP4426675A1 (https=) |
| JP (1) | JP2024540282A (https=) |
| KR (1) | KR20240095294A (https=) |
| CN (1) | CN117177959A (https=) |
| AU (1) | AU2022381220B2 (https=) |
| CA (1) | CA3236624A1 (https=) |
| IL (1) | IL312175A (https=) |
| WO (1) | WO2023078604A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021268204A1 (en) | 2020-05-08 | 2022-12-08 | Psilera Inc. | Novel compositions of matter and pharmaceutical compositions |
| IL308816A (en) | 2021-05-25 | 2024-01-01 | Atai Therapeutics Inc | New n,n-dimethyltryptamine salts and crystalline salt forms |
| WO2023018864A1 (en) | 2021-08-12 | 2023-02-16 | Psilosterics, Llc | Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same |
| JP2024545787A (ja) | 2021-12-30 | 2024-12-11 | アタイ セラピューティクス， インコーポレイテッド | 一酸化窒素送達剤としてのジメチルトリプタミン類似体 |
| CA3247344A1 (en) * | 2022-06-09 | 2023-12-14 | Diamond Therapeutics Inc. | AMORPHIC PSILOCYBIN (A-POLYMORPHIC) |
| US12049447B2 (en) | 2022-06-30 | 2024-07-30 | Zylorion Health Inc. | Crystalline forms of compositions comprising psilocin and psilocybin |
| AU2023343417B2 (en) * | 2022-09-12 | 2026-02-19 | Tryp Therapeutics, Inc | Psilocin crystalline forms |
| WO2024180030A1 (en) | 2023-02-27 | 2024-09-06 | Cybin Irl Limited | Methods of treating depressive disorders with a psilocybin analog |
| WO2025019800A1 (en) * | 2023-07-19 | 2025-01-23 | Atai Therapeutics, Inc. | Novel prodrugs and conjugates of dimethyltryptamine and methods of using the same |
| US12280068B1 (en) | 2023-11-09 | 2025-04-22 | Zylorion Health Inc. | Uses of a co-crystal of psilocybin and psilocin |
| US20250302075A1 (en) * | 2024-04-01 | 2025-10-02 | Tsi Group Co., Ltd. | Compositions and methods of preparation of a clear, effervescent delivery form for nutritional ingredients |
| US20260021070A1 (en) * | 2024-07-19 | 2026-01-22 | Compass Pathfinder Limited | Subcutaneous formulations comprising psilocybin derivatives |
| CN119610304A (zh) * | 2024-12-10 | 2025-03-14 | 澳创新耐火材料(中山)有限公司 | 一种低值植物纤维材料重组防火门芯及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| PH12022551981A1 (en) * | 2020-02-04 | 2023-10-16 | Mindset Pharma Inc | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| WO2022195011A1 (en) * | 2021-03-18 | 2022-09-22 | Cybin Irl Limited | Psilocybin analogs, salts, compositions, and methods of use |
-
2022
- 2022-03-17 CN CN202280022029.2A patent/CN117177959A/zh active Pending
- 2022-09-20 CA CA3236624A patent/CA3236624A1/en active Pending
- 2022-09-20 US US18/707,825 patent/US20250213527A1/en active Pending
- 2022-09-20 AU AU2022381220A patent/AU2022381220B2/en active Active
- 2022-09-20 EP EP22783493.4A patent/EP4426675A1/en active Pending
- 2022-09-20 JP JP2024526529A patent/JP2024540282A/ja active Pending
- 2022-09-20 WO PCT/EP2022/076073 patent/WO2023078604A1/en not_active Ceased
- 2022-09-20 KR KR1020247017594A patent/KR20240095294A/ko active Pending
- 2022-09-20 IL IL312175A patent/IL312175A/en unknown